Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods

C R Charman, A J Venn, J C Ravenscroft, H C Williams, C R Charman, A J Venn, J C Ravenscroft, H C Williams

Abstract

Background: The Patient-Oriented Eczema Measure (POEM) is a validated, patient-derived assessment measure for monitoring atopic eczema severity, although further information on how different POEM scores translate into disease severity categories is needed for clinical trials, epidemiological research and audit.

Objectives: We sought to determine the relationship between Patient-Oriented Eczema Measure (POEM) scores (range 0-28) and two Global Questions (GQ1 and 2) concerning patients'/parents' views of the overall severity of their/their child's atopic eczema, in order to stratify POEM scores into five severity bands.

Methods: POEM scores and GQs were completed by 300 patients from general practice and 700 patients from dermatology outpatient clinics, including 300 adults aged ≥ 16 years and 700 children.

Results: The mean POEM score was 13·6 (range 0-28), and standard deviation (SD) was 7·2. Mean GQ1/GQ2 scores were 2·1/2·1, respectively (range 0-4 and SD 1·1 for both). The mean, mode and median of the GQ scores for each POEM score were used to devise possible POEM bandings. The proposed banding for POEM scores are: 0-2 (clear/almost clear); 3-7 (mild); 8-16 (moderate); 17-24 (severe); 25-28 (very severe), kappa coefficient 0·46.

Conclusions: Severity banding of the POEM will allow more clinically meaningful use in everyday clinical practice and as a core outcome measure in future atopic eczema research.

© 2013 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Figure 1
Figure 1
Patient-Oriented Eczema Measure (POEM), questionnaire for use in adults and children (or parents/carers) with atopic eczema.
Figure 2
Figure 2
Global questions, GQ1 and 2
Figure 3
Figure 3
Relationship between the Patient-Oriented Eczema Measure (POEM) scores and the mode, mean and median of the Global Question (GQ1) score. The proposed banding scale of POEM scores 0–2, 3–7, 8–16, 17–24 and 25–28 is shown.

References

    1. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67:1111–17.
    1. Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140:1513–19.
    1. Charman CR, Williams HC. Outcome measures of disease severity in atopic eczema. Arch Dermatol. 2000;136:763–9.
    1. Charman CR, Chambers C, Williams HC. Measuring atopic dermatitis severity in randomised controlled clinical trials: what exactly are we measuring? J Invest Dermatol. 2003;120:932–41.
    1. Ricci G, Dondi A, Patrizi A. Useful tools for the management of atopic dermatitis. Am J Clin Dermatol. 2009;10:287–300.
    1. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120:1389–98.
    1. Williams HC, Grindlay DJC. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin Exp Dermatol. 2009;35:12–15.
    1. National Institute for Health and Clinical Excellence. 2007. Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years. December. Available at: (last accessed October 2013)
    1. Thomas KS, Koller K, Dean T, et al. A multicentre randomized controlled trial of ion-exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET) Health Technol Assess. 2011;15:1–156.
    1. Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353–9.
    1. Armstrong AW, Kim RH, Idriss NZ, et al. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64:502–7.
    1. Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67:99–106.
    1. Williams HC, Burney PG, Hay RJ, et al. The UK Working Party's diagnostic criteria for atopic dermatitis. Br J Dermatol. 1994;131:383–416.
    1. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659–64.
    1. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31.
    1. Tofte S, Graeber M, Cherill R, et al. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11(Suppl. 2):48.
    1. Charman CR, Venn AJ, Williams HC, et al. Measuring atopic eczema severity visually; which variables are most important to patients? Arch Dermatol. 2005;141:1146–51.

Source: PubMed

3
S'abonner